医学
药品
小RNA
肝损伤
药物开发
药物毒性
生物信息学
翻译(生物学)
生物标志物
金标准(测试)
药理学
内科学
生物
基因
生物化学
信使核糖核酸
作者
Robert James Hornby,Philip Starkey Lewis,James W. Dear,Christopher E. Goldring,B. Kevin Park
标识
DOI:10.1586/17512433.2014.904201
摘要
Drug-induced liver injury (DILI) is a common form of adverse drug reaction seen within the clinic. Sensitive, specific and non-invasive biomarkers of liver toxicity are required to help diagnose hepatotoxicity and also to identify safety liabilities during drug development. Limitations exist in the current gold standard DILI biomarkers: alanine aminotransferase is not liver-specific and therefore gives rise to false-positive signals. Interest has grown in the potential of microRNAs (miRNAs) as biomarkers of DILI. Some miRNAs display remarkable organ specificity, can be measured sensitively and are stable in a wide range of biofluids. However, little is currently known about the mechanisms through which miRNAs are released from cells. Furthermore, a clinically suitable method to measure miRNAs has not yet been developed. This review aims to highlight the current research surrounding these markers and areas in which further work is required to establish these markers within clinical and pre-clinical settings.
科研通智能强力驱动
Strongly Powered by AbleSci AI